LONG-TERM OUTCOMES WITH EMICIZUMAB PROPHYLAXIS FOR SEVERE HAEMOPHILIA A WITHOUT FVIII INHIBITORS: EFFICACY AND SAFETY ANALYSES FROM HAVEN 3 & 4

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Jimenez-Yuste, V. [3 ]
Ventriglia, G. [4 ]
Niggli, M. [4 ]
Barlera, S. [5 ]
Hermans, C. [6 ]
Lehle, M. [4 ]
Chowdary, P. [7 ]
Jew, L. [8 ]
Windyga, J. [9 ]
Frenzel, L. [10 ]
Castaman, G. [11 ]
Pipe, S. W. [12 ]
机构：
[1] Univ Witwatersrand, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Parexel Int, Milan, Italy
[6] Catholic Univ Louvain UCLouvain, Univ Clin St Luke, Brussels, Belgium
[7] Royal Free London, Katharine Dormandy Haemophilia & Thrombosis Unit, London, England
[8] Genentech Inc, San Francisco, CA USA
[9] Inst Hematol & Transfus Med, Dept Hemostasis Disorders & Internal Med, Lab Hemostasis andMetabol Dis, Warsaw, Poland
[10] Necker Enfants Malades Hosp, Dept Hematol, Paris, France
[11] Careggi Univ Hosp, Florence, Italy
[12] Univ Michigan, Dept Pediat & Pathol, Ann Arbor, MI USA
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO135
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [21] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
    Pipe, Steven
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kavakli, Kaan
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Niggli, Markus
    Fijnvandraat, Karin
    BLOOD, 2023, 142
  • [22] EFFICACY OF RFVIIIFC VERSUS EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITHOUT INHIBITORS: MATCHING-ADJUSTED INDIRECT COMPARISON OF A-LONG AND HAVEN TRIALS
    Klamroth, R.
    Wojciechowski, P.
    Aballea, S.
    Diamand, F.
    Hakimi, Z.
    Nazir, J.
    Abad-Franch, L.
    Lethagen, S.
    Santagostino, E.
    Tarantino, M.
    VALUE IN HEALTH, 2020, 23 : S742 - S742
  • [23] Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
    Pipe, Steven W.
    Shima, Midori
    Lehle, Michaela
    Shapiro, Amy
    Chebon, Sammy
    Fukutake, Katsuyuki
    Key, Nigel S.
    Portron, Agnes
    Schmitt, Christophe
    Podolak-Dawidziak, Maria
    Bienz, Nives Selak
    Hermans, Cedric
    Campinha-Bacote, Avrita
    Kiialainen, Anna
    Peerlinck, Kathelijne
    Levy, Gallia G.
    Jimenez-Yuste, Victor
    LANCET HAEMATOLOGY, 2019, 6 (06): : E295 - E305
  • [24] Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors
    Chuansumrit, A.
    Sirachainan, N.
    Panuwannakorn, M.
    Wongwerawattanakoon, P.
    Kadegasem, P.
    Choeyprasert, W.
    Sasanakul, W.
    HAEMOPHILIA, 2013, 19 (03) : E182 - E183
  • [25] HAVEN 2 Updated Analysis: Multicentre, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Paediatric Patients with Haemophilia A with Inhibitors
    Young, G.
    Sidonio, R. F.
    Liesner, R.
    Oldenburg, J.
    Chang, T.
    Uguen, M.
    Dhalluin, C.
    Schmitt, C.
    Levy, G. G.
    Shima, M.
    Mahlangu, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 20 - 21
  • [26] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
    Pipe, Steven W.
    Collins, Peter
    Dhalluin, Christophe
    Kenet, Gili
    Schmitt, Christophe
    Buri, Muriel
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Young, Guy
    Oldenburg, Johannes
    Mancuso, Maria Elisa
    Kiialainen, Anna
    Chang, Tiffany
    Lehle, Michaela
    Fijnvandraat, Karin
    BLOOD, 2022, 140
  • [27] Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY)
    Jimenez-Yuste, Victor
    Peyvandi, Flora
    Klamroth, Robert
    Castaman, Giancarlo
    Shanmukhaiah, Chandrakala
    Rangarajan, Savita
    Garcia Chavez, Jaime
    Martinez, Raul
    Kenet, Gili
    Alzahrani, Hazaa
    Robson, Susan
    Schmitt, Christophe
    Kiialainen, Anna
    Meier, Oliver
    Ozelo, Margareth
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (08)
  • [28] Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
    Lentz, Steven R.
    Janic, Dragana
    Kavakli, Kaan
    Miljic, Predrag
    Oldenburg, Johannes
    Ozelo, Margareth C.
    Santagostino, Elena
    Suzuki, Takashi
    Salek, Silva Zupancic
    Korsholm, Lars
    Matytsina, Irina
    Tiede, Andreas
    HAEMOPHILIA, 2018, 24 (06) : E391 - E394
  • [29] Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A
    Wu, Yuefang
    Lu, Jingjing
    Zhou, Yin
    Li, Kuixing
    Liu, Ying
    Liu, Shufen
    Li, Zhuo
    Zhao, Yongqiang
    Poon, Man-Chiu
    Xiao, Juan
    HAEMOPHILIA, 2021, 27 (02) : 237 - 244
  • [30] Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study
    Pipe, Steven W.
    Pasi, John
    Lissitchkov, Toshko
    Ragni, Margaret V.
    Negrier, Claude
    Yu, Qifeng
    Poloskey, Stacey
    Mei, Baisong
    Andersson, Shauna R.
    BLOOD, 2020, 136
12345